Narmafotinib

Narmafotinib (AMP-945) is an orally active inhibitor of the enzyme focal adhesion kinase (FAK, KD=0.21 nM) . Narmafotinib inhibits autophosphorylation of 397Y-FAK in MDA-MB-231 cells with an IC50=7 nM and exhibits low general cellular toxicity (IC50=2.7 μM, MDA-MB-231 cells) . Narmafotinib can be used for anti-cancer study[1].

Product Specifications

CAS Number

[1393653-34-3]

Product Name Alternative

AMP-945

UNSPSC

12352005

Target

FAK

Type

Reference compound

Related Pathways

Protein Tyrosine Kinase/RTK

Applications

Cancer-Kinase/protease

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/narmafotinib.html

Concentration

10mM

Purity

99.86

Solubility

DMSO : 100 mg/mL (ultrasonic)

Smiles

O=C(CC1=C(CCC2=NC(NC3=CC=C(C4CCN(CC4)C)C=C3OC)=NC=C2C(F)(F)F)C=CC=C1)N

Molecular Formula

C28H32F3N5O2

Molecular Weight

527.58

References & Citations

[1]Amplia Therapeutics completes single-dose study of AMP945|[2]Street I, et al. Abstract LB-308: combination of CTx-0294945 a highly selective inhibitor of focal adhesion kinase with bevacizumab in pre-clinical models of breast cancer[J]. Cancer Research, 2012, 72 (8_Supplement) : LB-308-LB-308.